Tech Center 1600 • Art Units: 1647
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17923872 | METHODS FOR TREATING INFLAMMATORY AND AUTOIMMUNE DISORDERS | Non-Final OA | President and Fellows of Harvard College |
| 18053325 | BISPECIFIC ANTIBODIES THAT BIND TO B7H3 AND NKG2D | Non-Final OA | Xencor, Inc. |
| 17821665 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 17767857 | ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF | Final Rejection | Arizona Board of Regents on Behalf of Arizona State University |
| 17922319 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL RECOGNITION SITES | Non-Final OA | Washington University |
| 17741271 | METHOD FOR BIOMATERIAL FUNCTIONALIZATION WITH IMMOBILIZED EXTRACELLULAR VESICLES | Final Rejection | Carnegie Mellon University |
| 18173052 | METHODS FOR QUANTIFYING POTENCY OF REGENERATIVE IMMUNOTHERAPIES | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18312144 | METHODS FOR IMPROVING T CELL EFFICACY | Non-Final OA | IMMATICS US, INC. |
| 18052131 | IMMUNOSILENCING Fc VARIANTS | Final Rejection | VISTERRA, INC. |
| 18073663 | COMPOSITIONS AND METHODS FOR TREATING AND SUPPRESSING ALLERGIC RESPONSES | Non-Final OA | IgGenix, Inc. |
| 17932057 | CLEAVABLE LINKERS | Non-Final OA | Xilio Development, Inc. |
| 18011605 | MATERIALS AND METHODS OF TREATING CANCER | Non-Final OA | MONOPTEROS THERAPEUTICS, INC. |
| 17800405 | NON-PROTEIN A PURIFICATION METHOD FOR ADALIMUMAB | Final Rejection | PRESTIGE BIOPHARMA PTE LTD. |
| 17777828 | METHODS FOR PROVIDING CONTINUOUS THERAPY AGAINST PNAG COMPRISING MICROBES | Final Rejection | ALOPEXX, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy